Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Revenue (2018 - 2025)

TransMedics has reported Revenue over the past 8 years, most recently at $160.8 million for Q4 2025.

  • Quarterly results put Revenue at $160.8 million for Q4 2025, up 32.18% from a year ago — trailing twelve months through Dec 2025 was $605.5 million (up 37.13% YoY), and the annual figure for FY2025 was $605.5 million, up 37.13%.
  • Revenue for Q4 2025 was $160.8 million at TransMedics, up from $143.8 million in the prior quarter.
  • Over the last five years, Revenue for TMDX hit a ceiling of $160.8 million in Q4 2025 and a floor of $5.4 million in Q3 2021.
  • Median Revenue over the past 5 years was $59.4 million (2023), compared with a mean of $70.6 million.
  • Biggest five-year swings in Revenue: crashed 32.11% in 2021 and later soared 374.47% in 2022.
  • TransMedics' Revenue stood at $8.5 million in 2021, then skyrocketed by 267.17% to $31.4 million in 2022, then surged by 158.72% to $81.2 million in 2023, then skyrocketed by 49.83% to $121.6 million in 2024, then surged by 32.18% to $160.8 million in 2025.
  • The last three reported values for Revenue were $160.8 million (Q4 2025), $143.8 million (Q3 2025), and $157.4 million (Q2 2025) per Business Quant data.